Search Results 1441-1450 of 17433 for Absence

1. Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies - Mayo Clinic

   ... absence of measurable m-protein, serum FLC ≥10 mg/dL, and abnormal serum immunoglobulin kappa lambda FLC ratio (<0.26 or >1.65). Patients must have ...

2. Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

   In the absence of rapidly progressing disease, the interval from prior treatment to time of study drug administration should be at least 2 weeks for ...

3. Publications - Tsung-Teh Wu, M.D., Ph.D. - Mayo Clinic

   Neuroendocrine Cells Are Commonly Absent in the Intestinal Crypts in Autoimmune Enteropathy. Am J Surg Pathol. 2020 Aug; 44 (8):1130-1136. View PubMed ...

4. A Study to Compare Nivolumab or Brentuximab Vedotin Plus Combination Chemotherapy to Treat Patients with Newly-diagnosed Stage III-IV Classic Hodgkin Lymphoma - Mayo Clinic

   Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.

5. HT-3951 vs. Placebo in Stroke Rehabilitation - Mayo Clinic

   Absent proprioception at the elbow or shoulder joints; Excessive spasticity in the affected elbow, defined as a score of greater than or equal to 3 on the ...

6. Sudden cardiac arrest - Symptoms and causes - Mayo Clinic

   This medical emergency involves sudden loss of all heart activity. Learn how fast, appropriate care may help prevent death.

7. Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas - Mayo Clinic

   Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions. If the patient consents ...

8. Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis - Mayo Clinic

   ... absence of contraindications * Participants on azathioprine treatment at Screening must be switched to MPA prior to randomization * Receipt of at least one ...

9. Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients - Mayo Clinic

   ... absence of an established hereditary coagulopathy. Treatment with a complement inhibitor (e.g., Soliris [eculizumab], Berinert [C1-INH], Cinryze [C1-INH]) ...

10. A Study to Better Understand Why Patients Gain Weight After Undergoing Liver Transplantation - Mayo Clinic

    Absence of other diseases (structural or metabolic) which could interfere with interpretation of the study results; Body mass index of 18‑45kg/m²; Females ...